BioNTech Investor Day Presentation Deck
BALB/C
BNT152 + BNT153
Therapeutic efficacy of BNT152 + BNT153 in combination with RNA vaccination
0
CT26 s.c.
▲ Treatment
10 17 24 31 100
+
HA
0
C57BL/6 H
CT26: "hot tumor" model
Therapeutic efficacy of IL-2 and IL-7 RiboCytokines ± RNA vaccination in a "hot tumor" model¹
Vaccine + BNT152+153
CR 10/11
TC-1 s.c.
12 17 24
+
+
A
31 73
HA
▲ Treatment
▲ Immunophenotyping (blood)
2048
1024-
512
TC-1: "cold tumor" model
Tumor size (mm³)
NEBEH NEB42
Tumorsize (mm³)
▬▬▬▬▬▬▬▬
256
128
64-
32
16
8
Vaccine
CR 0/11
2048
1024
0
25
100 0
25 50 75
50 75 100
Days after tumor inoculation Days after tumor inoculation
512-
256
128
64
32
16
Vaccine BNT152
BNT152+153
CR 0/15
CR 2/11
8
4
2
0 25 50 75
Days after tumor inoculation
Therapeutic efficacy of IL-2 + IL-7 depends on RNA vaccination in an advanced "cold tumor" model²
Vaccine + BNT152
Vaccine + BNT153
CR 0/15
CR 7/11
25 50 75 100
0 25 50 75 100 0
Days after tumor inoculation Days after tumor inoculation
Vaccine + BNT153
CR: 0/15
100 0
25 50 75 100 0 25 50 75 100
Days after tumor inoculation Days after tumor inoculation
Per cent survival
1 Kranz LM, et al. SITC Annual Meeting 2019; Poster presentation 620; 2 Kranz LM, et al. CIMT Annual Meeting 2021; ePresentation.
100⠀⠀⠀
0
25 50 75 100
Days after tumor inoculation
75-
50-
25
Vaccine + BNT152+153
CR 7/15
MKU
0
100-
75-
50-
25-
0
25
75
50
Days after tumor inoculation
0
25
50
75
Days after tumor inoculation
****
ns
100
NUMM
100
Vaccine
*
RiboCytokines
+
++
+ + +
Vaccine
+
Vaccine antigen: gp70
+ +
+
BNT153
+
+
+ + +
BNT152
BNT153
BNT152
Vaccine antigen: E7
BIONTECH
147View entire presentation